ArticleDiscover oncology2025
Novel nomograms for predicting overall survival and cancer-specific survival in invasive lobular carcinoma of the breast.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a ferroptosis-related gene signature for prognostic prediction and therapeutic target identification in invasive lobular carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeCurrently, the clinical diagnosis and treatment for invasive lobular carcinoma of the breast (ILC) often draw on the treatment approaches used for invasive ductal carcinoma (IDC), despite significant differences between the two. Studies evaluating the risk and prognosis of ILC are limited; thus, our goal was to construct a predictive model for the prognosis of ILC.
methodsClinical data of patients diagnosed with unilateral primary ILC from 2010 to 2015 were acquired from the SEER database. Independent prognostic factors affecting patients' overall survival (OS) and cancer-specific survival (CSS) were determined through univariate and multivariate analyses based on COX proportional hazards model and Fine-Gray competing risks model. Nomograms were constructed to forecast the 1-year, 3-year, and 5-year OS and CSS of the patients.
resultsA total of 6,616 patients with ILC were included, with 1,083 deaths, of which 541 were attributed to ILC, and 542 to other causes. The univariate and multivariate analyses indicated that age, N stage, stage, surgery, PR status, radiotherapy, and brain metastasis are independent risk factors for OS of ILC patients, while age, N stage, stage, surgery, PR status, and brain metastasis are independent risk factors for CSS of ILC patients. The C-index, area under the ROC curve, and calibration curve of the 1-, 3-, and 5-year OS and CSS prediction models confirmed that it had good predictive capability.
conclusionsThis study has developed subtype-specific predictive models for OS and CSS of patients with ILC, offering clinicians a regimen. Reference for assessing patient prognosis and formulating individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.